

Research

Open Access

Cellular localization of kinin B₁ receptor in the spinal cord of streptozotocin-diabetic rats with a fluorescent [N^α-Bodipy]-des-Arg⁹-bradykinin

Sébastien Talbot¹, Patrick Théberge-Turmel¹, Dalinda Liazoghli², Jacques Sénécal¹, Pierrette Gaudreau³ and Réjean Couture*¹

Address: ¹Department of Physiology, Faculty of Medicine, Université de Montréal, C.P. 6128, Succursale Downtown, Montréal, Québec, H3C 3J7, Canada, ²The Montreal Neurological Institute and Hospital, McGill University, 3801 University Street, Montreal, Québec, H3A 2B4, Canada and ³Laboratory of Neuroendocrinology of Aging, Centre Hospitalier de l'Université de Montréal Research Center, Angus Technopole, Montréal, Québec, H1W 4A4, Canada

Email: Sébastien Talbot - sebastien.talbot@umontreal.ca; Patrick Théberge-Turmel - patrick.theberge-turmel@usherbrooke.ca; Dalinda Liazoghli - dalinda.Liazoghli@mcgill.ca; Jacques Sénécal - jacques.senecal@umontreal.ca; Pierrette Gaudreau - pierrette.gaudreau@umontreal.ca; Réjean Couture* - rejean.couture@umontreal.ca

* Corresponding author

Published: 26 March 2009

Received: 5 November 2008

Journal of Neuroinflammation 2009, **6**:11 doi:10.1186/1742-2094-6-11

Accepted: 26 March 2009

This article is available from: <http://www.jneuroinflammation.com/content/6/1/11>

© 2009 Talbot et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: The kinin B₁ receptor (B₁R) is upregulated by pro-inflammatory cytokines, bacterial endotoxins and hyperglycaemia-induced oxidative stress. In animal models of diabetes, it contributes to pain polyneuropathy. This study aims at defining the cellular localization of B₁R in thoracic spinal cord of type I diabetic rats by confocal microscopy with the use of a fluorescent agonist, [N^α-Bodipy]-des-Arg⁹-BK (BdABK) and selective antibodies.

Methods: Diabetes was induced by streptozotocin (STZ; 65 mg/kg, i.p.). Four days post-STZ treatment, B₁R expression was confirmed by quantitative real-time PCR and autoradiography. The B₁R selectivity of BdABK was determined by assessing its ability to displace B₁R [¹²⁵I]-HPP-desArg¹⁰-Hoe 140 and B₂R [¹²⁵I]-HPP-Hoe 140 radioligands. The *in vivo* activity of BdABK was also evaluated on thermal hyperalgesia.

Results: R was increased by 18-fold (mRNA) and 2.7-fold (binding sites) in the thoracic spinal cord of STZ-treated rats when compared to control. BdABK failed to displace the B₂R radioligand but displaced the B₁R radioligand (IC₅₀ = 5.3 nM). In comparison, IC₅₀ values of B₁R selective antagonist R-715 and B₁R agonist des-Arg⁹-BK were 4.3 nM and 19 nM, respectively. Intraperitoneal BdABK and des-Arg⁹-BK elicited dose-dependent thermal hyperalgesia in STZ-treated rats but not in control rats. The B₁R fluorescent agonist was co-localized with immunomarkers of microglia, astrocytes and sensory C fibers in the spinal cord of STZ-treated rats.

Conclusion: The induction and up-regulation of B₁R in glial and sensory cells of the spinal cord in STZ-diabetic rats reinforce the idea that kinin B₁R is an important target for drug development in pain processes.

Background

Kinins are vasoactive peptides and central mediators acting through the activation of two G-protein-coupled receptors (R) denoted as B₁ and B₂ [1,2]. The B₂R is widely and constitutively expressed in central and peripheral tissues and is activated by its preferential agonists bradykinin (BK) and Lys-BK. The B₁R is activated by the active metabolites des-Arg⁹-BK and Lys-des-Arg⁹-BK and has a low level of expression in healthy tissues. The latter receptor is upregulated after exposure to pro-inflammatory cytokines, bacterial endotoxins, and hyperglycaemia-induced oxidative stress [3-7].

An important role for kinin B₁R has been postulated in nociception and pain [8-10]. B₁R knock out mice are less sensitive to pro-inflammatory pain stimuli and to spinal sensitization [11-13]. B₁R partakes to mechanical and/or thermal hyperalgesia induced by cytokines [14,15] through peripheral protein kinase C activation [16] and in the formalin test [17,18]. It also contributes to neuropathic pain after peripheral nerve injury [18-23] or after the induction of type 1 diabetes with streptozotocin (STZ) [24-27] and type 2 diabetes with high glucose feeding [7,28,29]. Thermal hyperalgesia was evoked by intraspinal stimulation of B₁R in STZ-diabetic rats [9].

Basal expression of B₁R was reported in the rat and human spinal cord dorsal horn as well as in rat dorsal root ganglion and small caliber primary sensory neurons [30-32]. Autoradiographic B₁R binding sites are increased and distributed all over the grey matter of the spinal cord after peripheral nerve injury [22] and in models of diabetes [7,29,33]. This spatial distribution of B₁R binding sites suggests that this receptor is not limited to primary sensory afferents but could also be present on spinal cord microglia and astrocytes.

To consolidate the role of B₁R in pain polyneuropathy, its cellular distribution was investigated in the spinal cord of STZ-induced B₁R with a newly developed fluorescent agonist named [N^α-Bodipy]-des-Arg⁹-BK (BdABK). The B₁R selectivity of BdABK was determined by assessing its ability to displace B₁R ([¹²⁵I]-HPP-desArg¹⁰-Hoe 140) and B₂R ([¹²⁵I]-HPP-Hoe 140) radioligands by autoradiography. Moreover, the displacement of BdABK fluorescent labeling by B₁R antagonists (R-715 and SSR240612) was assessed by confocal microscopy. We also investigated the *in vivo* activity of BdABK in comparison with its native agonist on thermal hyperalgesia in both STZ-treated and control rats. Appropriate selective antibodies were used in confocal microscopy to co-localize B₁R on astrocytes, microglia and sensory C fibers in STZ-diabetic rats. The induction and overexpression of B₁R in the spinal cord of STZ-diabetic rats was confirmed by qPCR and autoradiography. Experiments were achieved 4 days after STZ admin-

istration because previous studies showed that spinal cord B₁R was maximally up-regulated and engaged in thermal hyperalgesia 2 days after STZ treatment [9,33].

Methods

Animals and treatments

All research procedures and the care of the animals were in compliance with the guiding principles for animal experimentation as enunciated by the Canadian Council on Animal Care and were approved by the Animal Care Committee of our University. Male Sprague-Dawley rats (200-225 g, Charles River, St-Constant, Que., Canada) were housed two per cage, under controlled conditions of temperature (23 °C) and humidity (50%), on a 12 h light-dark cycle and allowed free access to normal chow diet (Charles River Rodent) and tap water.

STZ treatment

Rats were used 5 days after their arrival and injected under low light with freshly prepared STZ (65 mg/kg; i.p.; Sigma-Aldrich, Oakville, ON, Canada). Age-matched controls were injected with vehicle (sterile saline 0.9%, pH. 7.0) [33]. Glucose concentrations were measured, with a commercial blood glucose-monitoring kit (Accusoft; Roche Diagnostics, Laval, Que., Canada), in blood samples obtained from the tail vein, in non-fasting animals, before STZ injection, and 4 days after treatment. Only STZ-treated rats whose blood glucose concentration was higher than 20 mM were considered as diabetic.

Synthesis of [N^α-Bodipy]-des-Arg⁹-BK

BdABK was synthesized using 4,4-difluoro-5,7-dimethyl-4-bora-3a, 4a-diaza-s-indacene-3-propionic acid succinimidyl ester (BODIPY[®] FL SE, Molecular Probes/Invitrogen Canada Inc, Burlington, ON; emission 510 nm) and des-Arg⁹-BK (Bachem Bioscience inc., King of Prussia, PA, USA). Des-Arg⁹-BK was solubilized in 100 mM NaHCO₃ 0.1 M (pH 8.4), at a concentration of 1 mg/ml and two equivalents of BODIPY[®] FL SE, solubilized in degassed dimethyl sulfoxide, at a concentration of 5 mg/ml was added. Completion of the reaction was achieved in 2 h, at ambient temperature, under continuous agitation. The fluorescent peptide was lyophilized and purified by C18 reverse-phase HPLC as previously described [34,35]. The purity of the peptide was ≥ 98% as assessed by analytical HPLC (UV and fluorescence detection).

Tissue preparation for autoradiography and microscopy

Four days after injection of STZ, rats were anaesthetized with CO₂ inhalation and then decapitated. Upper thoracic spinal cord (T3-T7) was removed and frozen in 2-methylbutane (cooled at -40 °C following exposure to liquid nitrogen) and stored at -80 °C. Few days later, spinal cords were mounted in a gelatin block and serially cut into 20-μm thick coronal sections with a cryostat. Thus the sec-

tions were thaw-mounted on 0.2% gelatin-0.033% chromium potassium sulfate-coated slides and kept at -80°C for 1 month to allow the adhesion of sections to the coverslip glasses.

Confocal microscopy

Slides preparation

On the day of experiments, sections were thawed at room temperature for 10 min to enhance sections adhesion. They were pre-incubated for 10 min in 25 mM PIPES- NH_4OH buffer (pH 7.4) to allow degradation of endogenous kinins which could occupy receptors. Sections were exposed for 90 min to 50 μM BdABK. Thereafter, slides were washed twice (1 min) in PIPES and fixed with 4% para-formaldehyde [36]. Slides were washed three times (5 min) and then exposed to 1 M of glycine for 90 min to eliminate autofluorescence from aldehyde-fixed tissue. Tissues were permeabilized for 45 min with 0.1% Triton X-100.

Immunolabeling protocol

Slides were incubated with a blocking buffer (25 mM PIPES buffer supplemented with 3% bovine serum albumin (BSA) and 3% donkey serum) to prevent non-specific labeling. Antibodies were diluted in blocking buffer. A direct marker of DNA (TOPRO-3; Molecular Probes, Eugene, OR) was used at concentration of 1:5000. Rabbit anti-Ionized calcium binding adapter molecule 1 (anti-IBA-1, Wako, Richmond, VA) at a concentration of 2 $\mu\text{g}/\text{ml}$ was used to label microglia [37-39]. Chicken anti-Glial fibrillary acidic protein (anti-GFAP, Chemicon, Hornby, ON) at a concentration of 1:500 was used as a specific marker of astrocytes [40]. Rabbit anti-calcitonin-gene-related peptide (CGRP) (Chemicon, Hornby, ON) at a concentration of 1:2000 was used as marker of sensory C fibers [41]. Mouse anti-transient receptor potential vanilloid 1 (TRPV1) (Chemicon, Hornby, ON) at a concentration of 1 $\mu\text{g}/\text{ml}$ was used to label capsaicin receptor expressed on primary afferents [42]. Secondary antibodies were rhodamine anti-mouse (Chemicon, Hornby, ON) 1:500; cy5 anti-chicken (Chemicon, Hornby, ON) 1:500 and rhodamine anti-rabbit (Chemicon, Hornby, ON) 1:500.

Coverslip and microscopy

Slides were washed 3 times (5 min), mounted with coverslip, fixed with mowiol (12 h at room temperature) and

stored at -4°C for 1 month or used in confocal microscopy.

SYBR green-based quantitative RT-PCR

Four days after injection of STZ, rats were anaesthetized with CO_2 inhalation and then decapitated. The thoracic spinal cord (T1-T2) was isolated and approximately 10 mg of tissue were put in RNA later stabilization reagent (QIAGEN, Valencia, CA, USA). Total RNA was extracted from tissue according to the manufacturer's instructions. First-strand cDNA synthesized from 400 ng total RNA with random hexamer primers was used as template for each reaction with the QuantiTect Rev Transcription Kit (QIAGEN). SYBR Green-based real-time quantitative PCR using Mx3000p device for signal detection (Stratagene, La Jolla, CA, USA) was performed as described [43]. PCR was performed in SYBR Green Master mix (QIAGEN) with 300 nM of each primer. For standardization and quantification, rat 18S was amplified simultaneously. The primer pairs were designed by Vector NTI software and used [6] (Table 1).

PCR conditions were as follows: 95°C for 15 min, followed by 46 cycles at 94°C for 15 s, 60°C for 30 s and 72°C for 30 s. The cycle threshold (Ct) value represents the cycle number at which a fluorescent signal rises statistically above background [44]. The relative quantification of gene expression was analyzed by the $2^{-\Delta\Delta\text{Ct}}$ method [45].

Quantitative autoradiography

Specific binding sites of [^{125}I]-HPP-desArg 10 -Hoe 140 and [^{125}I]-HPP-Hoe 140

The radioligands for kinin B_1R , HPP-desArg 10 -Hoe140 (3-(4 hydroxyphenyl) propionyl-desArg 9 -D-Arg 0 [Hyp 3 , Thi 5 , D-Tic 7 , Oic 8]Bradykinin) and kinin B_2R , HPP-Hoe140 (3-(4 hydroxyphenyl) propionyl-D-Arg 0 [Hyp 3 , Thi 5 , D-Tic 7 , Oic 8]Bradykinin) were synthesized and kindly provided by Dr Witold Neugebauer (Dept Pharmacology, University of Sherbrooke, Sherbrooke, Que., Canada). They were iodinated by the chloramine T method [46]. On the day of experiments, sections were incubated at room temperature for 90 min in 25 mM PIPES- NH_4OH buffer (pH 7.4) containing: 1 mM 1,10-phenanthroline, 1 mM dithiothreitol, 0.014% bacitracin, 0.1 mM captopril, 0.2% bovine

Table 1: PCR primer pairs used in this study

	Sequences	Position	Gen Bank
18S Forward	5' TCA ACT TTC GAT GGT AGT CGC CGT 3'	363 – 386	X01117
18S Reverse	5' TCC TTG GAT GTG GTA GCC GTT TCT 3'	470 - 447	
B_1 receptor Forward	5' GCA GCG CTT AAC CAT AGC GGA AAT 3'	367 – 391	NM_030851
B_1 receptor Reverse	5' CCA GTT GAA ACG GTT CCC GAT GTT 3'	478 - 454	

serum albumin (protease free) and 7.5 mM magnesium chloride in the presence of 200 pM of [¹²⁵I]-HPP-desArg¹⁰-Hoe 140 or [¹²⁵I]-HPP-Hoe 140 (specific activity: 2000 cpm/fmol or 1212 Ci/mmol) [29,33]. Non-specific binding was determined in the presence of 1 μM of unlabeled B₁R antagonist: R-715 (AcLys [D-βNal⁷, Ile⁸]des-Arg⁹-BK) [1] or of 1 μM of unlabeled B₂R antagonist: Hoe 140 (Icatibant or JE 049, Jerini AG, Berlin, Germany) [47]. At the end of the incubation period, slides were transferred sequentially through four rinses of 4 min each in 25 mM PIPES (pH 7.4; 4°C) dipped for 15s in distilled water (4°C) to remove the excess of salts, and then air-dried. Kodak Scientific Imaging Films BIOMAX™ MR® (Amersham Pharmacia Biotech Canada) were juxtaposed onto the slides in the presence of [¹²⁵I]-microscales and exposed at room temperature for 7 days. The films were developed (GBX developer) and fixed (GBX fixer). Autoradiograms were quantified by densitometry using an MCID™ image analysis system (Imaging Research, St. Catharines, ON, Canada). A standard curve from [¹²⁵I]-microscales was used to convert density levels into femtomoles per milligram of protein [48]. Specific binding was determined by subtracting values of nonspecific binding from that of total binding.

Specificity of BdABK

To assess the specificity of BdABK for B₁R, competition curves were performed in autoradiography by incubating 200 pM of [¹²⁵I]-HPP-desArg¹⁰-Hoe 140 with increasing concentrations (10⁻¹⁰ to 10⁻⁶ M) of R-715 (selective B₁R antagonist, kindly provided by Dr Domenico Regoli, Pharmacology, University of Ferrara, Italy), des-Arg⁹-BK (dABK, selective B₁R agonist, Bachem Bioscience inc., King of Prussia, PA, USA) and BdABK. Moreover, competition curves were performed by incubating 200 pM of [¹²⁵I]-HPP-Hoe 140 with increasing concentrations (10⁻¹⁰ to 10⁻⁶ M) of Hoe 140 (selective B₂R antagonist) and BdABK. Each concentration of each competitor was tested on 4 sections per rat from 7 different rats. Those sections were exposed to the film, and total binding was calculated as described above. Moreover, the specificity of BdABK was determined in confocal microscopy by the displacement of fluorescent labeling with the addition of 10⁻⁵ M R-715 or SSR240612 [(2R)-2-[(3R)-3-(1,3-benzodioxol-5-yl)-3-[[6-methoxy-2-naphthyl]sulfonyl]amino]propanoyl]amino]-3-(4-[2R, 6S]-2,6 dimethylpiperidinyl)methyl]phenyl)-N-isopropyl-N-ethylpropanamide hydrochloride] (kindly provided by Dr Pierre Carayon, Sanofi-Aventis, Montpellier, France) [18] to the incubation medium.

Microglial cell culture

Primary cell culture method

Mixed glial cultures were prepared following the protocol of McCarthy and de Vellis [49] with some modifications. Briefly, forebrains were dissected out from one litter of 2-

day-old Sprague-Dawley rat pups and the meninges were stripped off before enzymatic and mechanical dissociation. For enzymatic dissociation, HBSS containing 0.25% trypsin (Gibco 15090-046) was used. The tissue-trypsin suspension was incubated for 20 min at 37°C in a water bath with intermittent shaking. After the waiting time for the trypsin digestion is over we added to the tissue-trypsin suspension a mixture of prewarmed DMEM/Dnase I (Sigma DN-25, Dnase I final concentration 0.25 mg/ml) followed by an incubation for 4 min at 37°C. The resulting suspension was dispersed by a mild mechanical trituration which consisted in the passage through 18-, 22- and 25-gauge needles. This cell suspension was then filtered through 70 μm strainer (BD Falcon 352350). After extensive washes in prewarmed HBSS, these dissociated cells were resuspended and plated in 75-cm² Falcon tissue-culture flasks (BD Biosciences) previously coated with 10 μg/ml poly-D-lysine (PDL). These mixed cells were growing at 37°C and 5% CO₂ in DMEM (Gibco) supplemented with 10% FBS, penicillin (100 units/ml), and streptomycin (100 mg/ml). The media was changed every 2 or 3 days thereafter.

At 10 days-*in-vitro*, a confluent monolayer of astrocytes was apparent, on top of which oligodendrocyte precursor cells and a loosely attached layer of phase-bright microglia was obtained. Microglia were collected by shaking the flasks for 1 h at 200 rpm at 37°C and 5% CO₂. Dislodged cells were resuspended and grown in culture medium for microglia [RPMI medium 1640 (Gibco) supplemented with 10% FBS, L-glutamine (1 mM), sodium pyruvate (1 mM), penicillin (100 units/ml), and streptomycin (100 mg/ml)]. The cells were allowed to adhere to the surface of PDL-coated coverslips (30 min at 37°C and 5% CO₂), and nonadherent cells were rinsed off.

Microglia cells preparation for confocal microscopy

Briefly, confluent cells were exposed to 300 nM of BK for 24 h to induce B₁R [50,51]. Control cells were exposed to vehicle. After incubation with BdABK, cells were washed, then fixed and permeabilized with 100% methanol previously stored at -20°C. The fixed cells were then processed as described for immunostaining.

Thermal hyperalgesia

Thermal hyperalgesia was assessed according to the method described by Hargreaves et al., 1988 [52] with minor modifications. Briefly, rats were placed (unrestrained) within a Plexiglass enclosure on a transparent glass floor and allowed to acclimatize for 20–30 min. An infrared beam that constitutes the noxious heat stimulus (Plantar test, Ugo Basile, Italy) was moved beneath the plantar surface of the hind paw. Thermal nociceptive threshold was defined as the latency (seconds) between the heat stimulus (46°C) onset and the paw withdrawal using a feedback-controlled shut-down unit. A cut-off time of 33

s was used to avoid tissue damage. Each paw was tested three times alternatively at minimum intervals of 3 min between stimulation to avoid sensitization of the hind paw. The rats were trained on several days prior to testing B_1R agonists. Thereafter, the thermal nociceptive threshold was assessed on 3 consecutive days as follows: day 1: baseline, saline and the first dose of des-Arg⁹-BK and BdABK (22.5 µg/kg); day 2: des-Arg⁹-BK and BdABK (225 µg/kg); day 3: des-Arg⁹-BK and BdABK (2250 µg/kg). Agonists were injected intraperitoneally at 1 h apart. This series of experiments was conducted in 3 control and 3 STZ-diabetic rats because the quantity of BdABK available for *in vivo* study was restricted. Thermal hyperalgesia was calculated as a percentage of the maximum possible effect (% MPE) according to the following formula: % MPE = $(100 \times (\text{drug latency} - \text{baseline latency}) / (\text{cut-off time} - \text{baseline latency}))$ [9]. The baseline latency corresponds to the average of the first three measurements.

Statistical analyses

All data were expressed as means \pm S.E.M. obtained from *n* rats. Statistical significance was determined with Student's *t*-test for unpaired samples or a one-way analysis of variance (ANOVA) followed by post-hoc Dunnett test for multiple comparisons. IC_{50} values were calculated by Graph Pad Prism 4.0 (GraphPad software, USA). Only probability (*P*) values less than 0.05 were considered to be statistically significant.




Figure 2
[N α -Bodipy]-des-Arg⁹-BK (BdABK) selectivity for B_1R was evaluated by confocal microscopy. While B_1R labeling in the presence of BdABK was absent in thoracic spinal cord of control rats (A), it was shown as green dots in STZ-treated spinal cord (B, and enlarged in C). B_1R labeling was absent in STZ-treated spinal cord when BdABK (50 µM) was co-incubated with $10^{-5}M$ SSR240612 (D) or $10^{-5}M$ R-715 (E). Background staining represents non specific autofluorescence. Scale bars = 20 µm (A, B, D, E) and 8.2 µm (C). Pictures are representative of a minimum of 4 sections per rat from 4 different STZ-diabetic rats.




Figure 1
 B_1R distribution in thoracic spinal cord of STZ-treated rats was shown by confocal microscopy with [N α -Bodipy]-des-Arg⁹-BK. Shown are pictures from low (i) to high magnification (v) of the dorsal horn. Scale bars = 200, 50, 20, 5 and 2.5 µm, respectively from (i) to (v). Pictures are representative of a minimum of 4 sections per rat from 4 different STZ-diabetic rats.

Results

B_1R fluorescent labeling and selectivity of BdABK

Figure 1 illustrates B_1R labeling with BdABK from low (i) to high (v) magnification (green dots) in dorsal horn of thoracic spinal cord of STZ-treated rats. As depicted in Figure 2, BdABK showed no labeling in control thoracic spinal cord (A), while the labeling of B_1R was apparent in thoracic spinal cord of STZ-treated rats as revealed by green dots (B). Selectivity and specificity of the labeling were demonstrated by the absence of BdABK labeling in STZ-spinal cord sections when the B_1R antagonists SSR240612 (D) and R-715 (E) were added at $10^{-5}M$.

B_1R and B_2R binding and IC_{50} value of BdABK

Competition experiments using 200 pM [¹²⁵I]-HPP-desArg¹⁰-Hoe 140 and 10^{-10} to 10^{-6} M of des-Arg⁹-BK, R-715, or BdABK revealed that kinin analogues decreased in a concentration-dependent manner the binding of [¹²⁵I]-HPP-desArg¹⁰-Hoe 140 in the thoracic spinal cord of STZ-treated rats (Fig. 3). The rank order of potency to inhibit total B_1R binding sites was R-715 = BdABK > des-Arg⁹-BK with IC_{50} values of 4.3 ± 0.2 nM, 5.3 ± 0.1 nM and 19 ± 0.2 nM, respectively. In contrast, BdABK (10^{-10} to 10^{-6} M) failed to inhibit the binding of 200 pM [¹²⁵I]-HPP-Hoe 140 to B_2R in the thoracic spinal cord of STZ-treated rats (Fig. 4). In comparison, same concentrations of Hoe 140 displaced B_2R binding sites with IC_{50} value of 1.33 ± 0.1 nM.

BdABK mediated *in vivo* thermal hyperalgesia

The *in vivo* effect of BdABK on pain behavior was assessed by determining its ability to induce thermal hyperalgesia upon intraperitoneal injection in STZ-treated rats. As




Figure 3
[N α -Bodipy]-des-Arg⁹-BK selectivity for B₁R was evaluated by quantitative autoradiography. R-715 (selective B₁R antagonist), des-Arg⁹-BK (selective B₁R agonist) and [N α -Bodipy]-des-Arg⁹-BK (fluorescent agonist of B₁R) displaced in a concentration-dependent manner, from 10⁻¹⁰ to 10⁻⁶ M, the total binding of 200 pM [¹²⁵I]-HPP-desArg¹⁰-Hoe 140 to B₁R. Data are means \pm SEM of 4 sections per rat from 7 different rats for each compound.




Figure 4
[N α -Bodipy]-des-Arg⁹-BK affinity for B₂R was evaluated by quantitative autoradiography. Increasing concentration (10⁻¹⁰ to 10⁻⁶ M) of Hoe 140 (selective B₂R antagonist) displaced total binding of 200 pM [¹²⁵I]-HPP-HOE-140 to B₂R. In contrast, same concentrations of [N α -Bodipy]-des-Arg⁹-BK (fluorescent B₁R agonist) did not displace the B₂R radioligand. Data are means \pm SEM of 4 sections per rat from 7 different rats for each compound.

expected, BdABK and des-Arg⁹-BK had no significant effect on the nociceptive threshold in control rats, yet both agonists caused thermal hyperalgesia in STZ-diabetic rats at 0.225 and 2.25 mg/kg. These effects were dose-dependent and significant when compared to saline or control (Fig. 5). BdABK was however slightly but significantly less potent than des-Arg⁹-BK to induce hyperalgesia at the highest dose. As exemplified by des-Arg⁹-BK, this response peaked at 15 min post-injection and was reversible after 30 min (Fig. 6).

B₁R mRNA expression assessed by qPCR

A low basal expression of kinin B₁R mRNA was detected in the spinal cord of control rats (Fig. 7). This expression was significantly increased (18-fold) in the spinal cord of STZ-diabetic rats.

Density of B₁R binding sites assessed by quantitative autoradiography

As presented in Figure 8, quantitative *in vitro* autoradiography showed an increase density of specific B₁R binding sites throughout the grey matter of the thoracic spinal cord in STZ-treated rats when compared to age-matched control spinal cord. B₁R binding sites (2.4 fmol/mg protein) in spinal cord of STZ-treated rats were 2.7-fold greater than those measured in control rats (0.9 fmol/mg protein).

B₁R colocalized on microglial cells in thoracic spinal cord

Figure 9 shows the colocalization of BdABK, TOPRO-3 and anti-IBA-1 in STZ thoracic spinal cord. Data suggest that B₁R is present on spinal microglial cells in STZ-diabetic rats.

B₁R colocalized in primary cultured microglial cells

Figure 10 shows the colocalization of BdABK, TOPRO-3 and anti-IBA-1 in primary microglial cell culture. B₁R was induced by a pre-treatment with 300 nM BK. About 95 \pm 2% of the primary cell culture showed a positive labeling




Figure 5
The ability of intraperitoneally injected [N α -Bodipy]-des-Arg⁹-BK and its native agonist, des-Arg⁹-BK, to alter the paw withdrawal threshold in STZ-treated and control rats. Data represent maximal effects and are the average of 3 readings taken at 9, 12 and 15 min post-injection in 3 rats per group. Statistical comparison to control (*) and 2250 μ g/kg des-Arg⁹-BK (+) are indicated by * + P < 0.05; ** P < 0.01; *** P < 0.001.

Change in nociceptive threshold to des-Arg⁹-BK (2.25 mg/kg, ip) in STZ-treated rats




Figure 6
Time-course effect of des-Arg⁹-BK (2.25 mg/kg, i.p.) on the nociceptive threshold in STZ-treated rats.
Data are means \pm SEM of 3 rats. Statistical comparison to time 0 (*) is indicated by ** P < 0.01.

with anti-IBA-1 confirming cell purity. Data suggest that B₁R can be induced *in vitro* on microglial cells.

B₁R colocalized on sensory C fibers in thoracic spinal cord

Figure 11 shows the colocalization of BdABK, anti-TRPV1 and anti-CGRP in the thoracic spinal cord of STZ-treated rats. Data suggest that B₁R and TRPV1 are co-localized on sensory C fibers in STZ-diabetic rats.

B₁R colocalized on astrocytes in thoracic spinal cord

Figure 12 shows the colocalization of BdABK and anti-GFAP in the spinal cord of STZ-treated rats. Data suggest that B₁R is also present on spinal astrocyte cells in STZ-diabetic rats.




Figure 7
B₁R mRNA expression in STZ-treated and control thoracic spinal cords was measured by quantitative real-time PCR. Data are means \pm SEM of (3 to 6) rats. Statistical comparison with control is indicated by * P < 0.05.




Figure 8
B₁R binding sites in STZ-treated and control thoracic spinal cords were measured by quantitative autoradiography. Specific density of B₁R binding sites are means \pm SEM of (7 to 8) rats. Statistical comparison with control is indicated by *** P < 0.001.

Discussion


This study is using a newly developed selective and high affinity fluorescent ligand enabling the cellular localization of B₁R on unfixed tissue. It provides the first evidence that B₁R is localized on microglial cells, astrocytes and sensory C fibers in the thoracic spinal cord of STZ-diabetic rats. This study also highlights the early upregulation of B₁R (mRNA and binding sites) in the thoracic spinal cord of hyperglycaemic STZ-treated rats.

Diabetes induces B₁R expression

STZ-diabetic rats provide an accessible model for studying the expression, the pharmacology and physiopathology of the B₁R in the central nervous system. Pharmacological data showed that functional B₁R was expressed in spinal cord of STZ-treated rats; its spinal activation led to sympathetically mediated increases of blood pressure and heart rate [53] and to thermal hyperalgesia [9]. Further autoradiographic and functional evidence for B₁R induction was demonstrated in the lung [54], spinal cord [33], retina [6,55] and brain [56] of STZ-diabetic rats. However, this is the first report on mRNA expression in thoracic spinal cord of STZ-diabetic rats by qPCR. Hyperglycaemia associated with type 1 diabetes can activate NF- κ B [57] which is known to induce B₁R [2,3,58]. Moreover, oxidative stress associated with diabetes was reported to be involved in the induction of B₁R [6,7,29,59].

[N^α-Bodipy]-des-Arg⁹-BK selectivity for B₁R


Experiments by autoradiography confirm that BdABK is highly selective for B₁R and does not bind to B₂R. Indeed, BdABK failed to displace the B₂R radioligand [¹²⁵I]-HPP-Hoe-140 while it displaced the B₁R radioligand, [¹²⁵I]-

**Figure 9**

STZ-treated thoracic spinal cord was exposed to TOPRO-3, a specific fluorescent dye for DNA (A). Microglia was identified with anti-IBA-1 (B). The B₁R was stained with the selective fluorescent agonist, BdABK (C). Colocalization of the three markers is shown in panel D. TOPRO-3 dye is blue (ext: 642 nm/em: 661 nm), anti-IBA-1 dye is red (ext: 550 nm/em: 570 nm) and BdABK dye is green (ext: 505 nm/em: 515 nm). Scale bar = 5.38 μm. Pictures presented are representative of a minimum of 4 sections per rat from 4 different animals.

HPP-desArg¹⁰-Hoe 140, with an IC₅₀ of 5.3 ± 0.1 nM in thoracic spinal cord of STZ-treated rats. Results also evidenced that B₂R binding sites were displaced by the selective antagonist, Hoe 140, with an IC₅₀ value of 1.3 ± 0.1 nM while B₁R binding sites were displaced by the natural B₁R agonist, des-Arg⁹-BK (IC₅₀ = 19 ± 0.2 nM) and by R-715, a selective B₁R peptide antagonist (IC₅₀ = 4.3 ± 0.2 nM). Comparison of IC₅₀ values suggests that the affinity of the B₁R agonist is increased by the addition of the Bodipy molecule. The stabilization of the N-terminus part of the peptide may contribute to prevent its degradation.

The reason for using 50 μM BdABK was based on preliminary study. The concentration of fluorescent probe needed to get a consistent labeling was higher than the IC₅₀ value most likely because BdABK binds to B₁R non-covalently and can be eliminated during the washout period of tissue sections. Signal amplification with radioactivity is also expected to be greater than that achieved with a fluorescent probe. BdABK showed no labeling in thoracic spinal cord of control rats which is in accordance with the inducible character of the B₁R and its virtual absence in healthy tissues. The elimination of B₁R label-

**Figure 10**

Rat microglial primary cultured cells were exposed for 24 h to 300 nM BK to increase B₁R expression. Then, they were exposed to TOPRO-3, a specific fluorescent dye for DNA (A), to anti-IBA-1, a specific antibody against microglia (B) and BdABK to stain B₁R (C). Colocalization of the three markers is shown in panel D. TOPRO-3 dye is blue (ext: 642 nm/em: 661 nm), anti-IBA-1 dye is red (ext: 550 nm/em: 570 nm) and BdABK dye is green (ext: 505 nm/em: 515 nm). Scale bar = 31.75 μm. Pictures presented are representative of 4 cultured cells samples from 4 different animals.

ling with BdABK after co-incubation with R-715 or SSR240612 confirms the specificity of the B₁R fluorescent ligand.

Interestingly, BdABK maintained its biological activity as B₁R agonist *in vivo*. Data obtained on the Hargreaves test revealed that BdABK was only slightly less potent than des-Arg⁹-BK to cause thermal hyperalgesia upon peripheral administration. This is consistent with the transient thermal hyperalgesia previously reported in the tail-flick test after intrathecal injection of des-Arg⁹-BK in rats made diabetics with STZ 24 h earlier [9]. Likewise, Gabra and Sirois [24] showed that intraperitoneal administration of des-Arg⁹-BK (400 μg/kg) in STZ-treated rats significantly reduced the paw withdraw threshold in the hot plate and tail-flick test.

Localization of B₁R

B₁R on microglial cells

Previous work by Noda and coworkers [50,51] showed that B₁R can be expressed in cultured rat microglia exposed to




Figure 11
STZ-treated spinal cord was exposed to anti-CGRP, a selective antibody of sensory C fibers (A). TRPV1 was labeled with anti-TRPV1 another marker of sensory C fibers (B). The B_1R was stained with the selective fluorescent agonist, BdABK (C). Colocalization of the three markers is shown in panel D. Anti-CGRP dye is blue (ext: 650 nm/em: 680 nm), anti-TRPV1 dye is red (ext: 550 nm/em: 570 nm), and BdABK dye is green (ext: 505 nm/em: 515 nm). Scale bar = 19.21 μ m. Pictures presented are representative of a minimum of 4 sections per rat from 4 different animals.

BK. We confirmed this result by using our fluorescent ligand in the same condition, thus providing additional evidence of its ability to bind B_1R in a pure rat microglia model. BK acting via B_2 receptors induces elevation of intracellular calcium leading to the phosphorylation and activation of NF- κ B by protein kinase C [60]. NF- κ B upregulates B_1R upon binding to its nuclear promoter [2].

A recent study has demonstrated that B_1R is involved in microglial migration toward rat brain lesion sites [61]. The presence of B_1R on spinal microglial cells is in keeping with a recent study suggesting that activated dorsal horn microglia is a crucial component of STZ-induced tactile allodynia, mediated in part, by extracellular signal-regulated protein kinase signaling [62]. Importantly, the development of tactile and cold allodynia in a rat model of insulin-resistance was blocked by the B_1R antagonist SSR240612 [28] and by two antioxidants (N-acetyl-L-cysteine and alpha-lipoic acid) known to prevent the induction of B_1R [7,29]. Taken together, these results suggest a critical role for microglial B_1R in generation of tactile allodynia, a manifestation of pain polyneuropathy. It




Figure 12
STZ-treated spinal cord was exposed to anti-GFAP, a specific antibody against astrocytes (A) and to BdABK (B). Colocalization between B_1R and the astrocytes is shown in panel C. Anti-GFAP dye is red (ext: 550 nm/em: 570 nm) and BdABK dye is green (ext: 505 nm/em: 515 nm). Scale bar = 7.27 μ m. Pictures presented are representative of a minimum 4 sections per rat from 4 different animals.

is possible that microglial B_1R is also involved in STZ-induced thermal hyperalgesia as this response was abolished by B_1R antagonists [5,24,27] and was absent in B_1R knockout mice treated with STZ [26].

B₁R on astrocytes

In addition, the present study provides the first evidence that thoracic spinal cord astrocytes bear the B_1R in STZ-diabetic rats. Astrocyte B_1R may represent another target for neuropathic or chronic pain. Emerging evidence suggests a critical role for astrocytes in the passage from acute to chronic and neuropathic pain. It seems that intracellular calcium level oscillation in astrocytes could spread through astrocytal network and thereby facilitate the formation of new synapses. These new synapses could establish neuronal contacts for maintaining and spreading pain sensation [63]. Moreover, astrocytes are known to release various inflammatory mediators that promote neuroimmune activation and can sensitize primary afferent sensory neurons contributing to development of neuropathic pain [64].

B₁R on sensory C fibers

Immunohistochemical data showed the presence of B_1R in DRG and superficial laminae of spinal cord dorsal horn

[30-32]. Those studies suggested a basal expression of B₁R in primary sensory C fibers of normal rat. This is consistent with the expression of B₁R in sensory C fibers of STZ-treated rats as revealed by the co-localization of B₁R, CGRP and TRPV1. Horowitz [65] described the crucial role of small A-delta and C fibers in generation of diabetic polyneuropathy and their sensitivity to hyperglycaemia. Ueda's studies [66,67] support the hypothesis that the generation of neuropathic pain is related to alterations in gene and protein expression in primary sensory neurons which could contribute to demyelination of A-delta fibers through the down-regulation of myelin protein such as MBP, MPZ and PMP22. Demyelinated A-delta fibers sprout and synapse with A-beta fibers resulting in the enhancement of pro-nociceptive neurotransmitter release which generated allodynia. The presence of B₁R on sensory C fibers is in agreement with an earlier pharmacological study that showed that the stimulation of B₁R with an agonist in the spinal cord of STZ-diabetic rats provokes thermal hyperalgesia via the release of substance P [9].

Basal B₁R expression in control rats

Authors failed to observe specific fluorescent labelling for B₁R in normal rats which is rather consistent with the negligible level of B₁R mRNA and binding sites. Moreover, intrathecal injection of B₁R agonists or antagonists failed to cause behavioural, cardiovascular or nociceptive responses in control rats, suggesting that the basal expression of B₁R is not functional in naïve rats [9,53]. Thus the function of the B₁R detected by immunohistochemistry in the spinal cord of rodents and human remains elusive. It is feasible that B₁R in control animals is uncoupled to G protein as demonstrated for other G-protein-coupled receptors [68,69]. Although it is possible that the immunological approach is more sensitive, we have evidence (unpublished data) showing that the commercially available B₁R antibodies (M-19) from SantaCruz Biotechnologies (Santa Cruz, CA, USA) are not specific for immunohistochemical detection since B₁R labeling persists in spinal cord isolated from B₁R knockout mice. The latter B₁R antibodies remain however suitable for Western blot analysis, suggesting that immunohistochemical studies reported with B₁R antibodies remain to be validated with the appropriate controls in mutant mice.

Conclusion

[N α -Bodipy]-des-Arg⁹-BK was found selective for B₁R with an IC₅₀ value of 5.3 \pm 0.1 nM in the rat spinal cord. Furthermore, BdABK maintains its biological activity as agonist as evidenced by its ability to induce thermal hyperalgesia in STZ-treated rats. This new fluorescent ligand enabled the detection of B₁R in primary microglial cell culture and on microglial cells, astrocytes and sensory C fibers in the thoracic spinal cord of STZ-diabetic rats. Because all these cells have been implicated in neuro-

pathic pain, the induction and up-regulation of the B₁R on these elements consolidate the idea that kinin B₁R is an important target for drug development in pain processes.

List of abbreviations

B₁R: kinin B₁ receptor; STZ: streptozotocin; qPCR: quantitative real-time PCR; BK: Bradykinin; BdABK: [N α -Bodipy]-des-Arg⁹-BK; BSA: bovine serum albumin; anti-IBA-1: anti-Ionized calcium binding adapter molecule 1; anti-GFAP: anti-Glial fibrillary acidic protein; anti-CGRP: anti-calcitonin-gene-related peptide; anti-TRPV1: anti-transient receptor potential vanilloid 1.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

ST performed animal treatments, Hargreaves test, real-time PCR analysis, confocal microscopy experiments and draft the manuscript. PTT helped designed the confocal microscopy protocol. DL performed *in vitro* microglia experiments. JS made cryostat tissue sections and autoradiography experiments. PG synthesized the fluorescent agonist. RC designed the study and revised the manuscript.

Acknowledgements

This work was supported by Grant-in-aids from the Canadian Diabetes Association (OG-3-07-2428-RC) and Canadian Institutes of Health Research (MOP-79471). S.T. holds a Studentship from the FRSQ (Fonds de la Recherche en Santé du Québec). Authors acknowledge Ms Julie Desroches and Dr Pierre Beaulieu for giving us access to the Hargreaves Apparatus and to Mr Michel Lauzon for his expert assistance in confocal microscopy.

References

- Regoli D, Nsa Allogho S, Rizzi A, Gobeil FJ: **Bradykinin receptors and their antagonists.** *Eur J Pharmacol* 1998, **348**:1-10.
- Leeb-Lundberg LM, Marceau F, Müller-Esterl W, Pettibone DJ, Zuraw BL: **International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences.** *Pharmacol Rev* 2005, **57**:27-77.
- Marceau F, Bachvarov DR: **Kinin receptors.** *Clin Rev Allergy Immunol* 1998, **16**:385-401.
- deBlois D, Horlick RA: **Endotoxin sensitization to kinin B(1) receptor agonist in a non-human primate model: haemodynamic and pro-inflammatory effects.** *Br J Pharmacol* 2001, **132**:327-35.
- Couture R, Girolami JP: **Putative roles of kinin receptors in the therapeutic effects of angiotensin I-converting enzyme inhibitors in diabetes mellitus.** *Eur J Pharmacol* 2004, **500**:467-85.
- Abdoun M, Talbot S, Couture R, Hassésian HM: **Retinal plasma extravasation in streptozotocin-diabetic rats mediated by kinin B(1) and B(2) receptors.** *Br J Pharmacol* 2008, **154**:136-43.
- Ismael MA, Talbot S, Carbonneau CL, Beauséjour CM, Couture R: **Blockade of sensory abnormalities and kinin B(1) receptor expression by N-Acetyl-L-Cysteine and ramipril in a rat model of insulin resistance.** *Eur J Pharmacol* 2008, **589**:66-72.
- Calixto JB, Cabrini DA, Ferreira J, Campos MM: **Kinins in pain and inflammation.** *Pain* 2000, **87**:1-5.
- Couture R, Harrisson M, Vianna RM, Cloutier F: **Kinin receptors in pain and inflammation.** *Eur J Pharmacol* 2001, **429**:161-76.

10. Rodi D, Couture R, Ongali B, Simonato M: **Targeting kinin receptors for the treatment of neurological diseases.** *Curr Pharm Design* 2005, **11**:1313-26.
11. Ferreira J, Campos MM, Pesquero JB, Araújo RC, Bader M, Calixto JB: **Evidence for the participation of kinins in Freund's adjuvant-induced inflammatory and nociceptive responses in kinin B1 and B2 receptor knockout mice.** *Neuropharmacol* 2001, **41**:1006-12.
12. Ferreira J, Campos MM, Araújo R, Bader M, Pesquero JB, Calixto JB: **The use of kinin B1 and B2 receptor knockout mice and selective antagonists to characterize the nociceptive responses caused by kinins at the spinal level.** *Neuropharmacol* 2002, **43**:1188-97.
13. Pesquero JB, Araújo RC, Heppenstall PA, Stucky CL, Silva JA Jr, Walther T, Oliveira SM, Pesquero JL, Paiva AC, Calixto JB, Lewin GR, Bader M: **Hypoalgesia and altered inflammatory responses in mice lacking kinin B1 receptors.** *Proc Natl Acad Sci USA* 2000, **97**:8140-5.
14. Perkins MN, Kelly DL: **Induction of bradykinin B1 receptors in vivo in a model of ultra-violet irradiation-induced thermal hyperalgesia in the rat.** *Br J Pharmacol* 1993, **110**:1441-4.
15. Davis AJ, Perkins MN: **The involvement of bradykinin B1 and B2 receptor mechanisms in cytokine-induced mechanical hyperalgesia in the rat.** *Br J Pharmacol* 1994, **113**:63-8.
16. Ferreira J, Trichês KM, Medeiros R, Cabrini DA, Mori MA, Pesquero JB, Bader M, Calixto JB: **The role of kinin B1 receptors in the nociception produced by peripheral protein kinase C activation in mice.** *Neuropharmacology* 2008, **54**:597-604.
17. Corrêa CR, Calixto JB: **Evidence for participation of B1 and B2 kinin receptors in formalin-induced nociceptive response in the mouse.** *Br J Pharmacol* 1993, **110**:193-8.
18. Gougat J, Ferrari B, Sarran L, Planchenault C, Poncelet M, Maruani J, Alonso R, Cudennec A, Croci T, Guagnini F, Urban-Szabo K, Martinolle JP, Soubrié P, Finance O, Le Fur G: **SSR240612 [(2R)-2-[[[(3R)-3-(1,3-benzodioxol-5-yl)-3-[[[(6-methoxy-2-naphthyl)sulfonyl]amino]propanoyl]amino]-3-(4-[[2R, 6S)-2,6-dimethylpiperidinyl]methyl]phenyl]-N-isopropyl-N-methylpropanamide hydrochloride], a new nonpeptide antagonist of the bradykinin B1 receptor: biochemical and pharmacological characterization.** *J Pharmacol Exp Ther* 2004, **309**:661-9.
19. Eckert A, Segond G von Banchet, Sopper S, Petersen M: **Spatio-temporal pattern of induction of bradykinin receptors and inflammation in rat dorsal root ganglia after unilateral nerve ligation.** *Pain* 1999, **83**:487-97.
20. Levy D, Zochodne DW: **Increased mRNA expression of the B1 and B2 bradykinin receptors and antinociceptive effects of their antagonists in an animal model of neuropathic pain.** *Pain* 2000, **86**:265-71.
21. Petersen M, Eckert AS, Segond G von Banchet, Heppelmann B, Klusch A, Kniffki KD: **Plasticity in the expression of bradykinin binding sites in sensory neurons after mechanical nerve injury.** *Neuroscience* 1998, **83**:949-59.
22. Petcu M, Dias JP, Ongali B, Thibault G, Neugebauer W, Couture R: **Role of kinin B1 and B2 receptors in a rat model of neuropathic pain.** *Int Immunop* 2008, **8**:188-96.
23. Werner MF, Kassuya CA, Ferreira J, Zampronio AR, Calixto JB, Rae GA: **Peripheral kinin B(1) and B(2) receptor-operated mechanisms are implicated in neuropathic nociception induced by spinal nerve ligation in rats.** *Neuropharmacology* 2007, **53**:48-57.
24. Gabra BH, Sirois P: **Role of bradykinin B(1) receptors in diabetes-induced hyperalgesia in streptozotocin-treated mice.** *Eur J Pharmacol* 2003, **5**:458:329.
25. Gabra BH, Sirois P: **Hyperalgesia in non-obese diabetic (NOD) mice: a role for the inducible bradykinin B1 receptor.** *Eur J Pharmacol* 2005, **514**:61-7.
26. Gabra BH, Merino VF, Bader M, Pesquero JB, Sirois P: **Absence of diabetic hyperalgesia in bradykinin B1 receptor-knockout mice.** *Regul Pept* 2005, **127**:245-8.
27. Gabra BH, Benrezzak O, Pheng LH, Duta D, Daull P, Sirois P, Nantel F, Battistini B: **Inhibition of type I diabetic hyperalgesia in streptozotocin-induced Wistar versus spontaneous gene-prone BB/Worcester rats: efficacy of a selective bradykinin B1 receptor antagonist.** *J Neuropathol Exp Neurol* 2005, **64**:782-9.
28. Dias JP, Ismael MA, Pilon M, de Champlain J, Ferrari B, Carayon P, Couture R: **The kinin B1 receptor antagonist SSR240612 reverses tactile and cold allodynia in an experimental rat model of insulin resistance.** *Br J Pharmacol* 2007, **152**:280-7.
29. Lungu C, Dias JP, França CE, Ongali B, Regoli D, Moldovan F, Couture R: **Involvement of kinin B1 receptor and oxidative stress in sensory abnormalities and arterial hypertension in an experimental rat model of insulin resistance.** *Neuropeptides* 2007, **41**:375-87.
30. Ma QP: **The expression of bradykinin B(1) receptors on primary sensory neurones that give rise to small caliber sciatic nerve fibers in rats.** *Neuroscience* 2001, **107**:665-73.
31. Ma QP, Heavens R: **Basal expression of bradykinin B(1) receptor in the spinal cord in humans and rats.** *Neuroreport* 2001, **12**:2311-4.
32. Wotherspoon G, Winter J: **Bradykinin B1 receptor is constitutively expressed in the rat sensory nervous system.** *Neurosci Lett* 2000, **294**:175-8.
33. Ongali B, Campos MM, Petcu M, Rodi D, Cloutier F, Chabot JG, Thibault G, Couture R: **Expression of kinin B1 receptors in the spinal cord of streptozotocin-diabetic rat.** *Neuroreport* 2004, **15**:2463-6.
34. Faure MP, Gaudreau P, Shaw I, Cashman NR, Beaudet A: **Synthesis of a biologically active fluorescent probe for labelling of neurotensin receptors.** *J Histochem Cytochem* 1994, **42**:755-763.
35. Veyrat-Durebex C, Pomerleau L, Langlois D, Gaudreau P: **Internalization and trafficking of the human and rat growth hormone-releasing hormone receptor.** *J Cell Physiol* 2005, **203**:335-344.
36. Witting C: **Immunofluorescence studies on formalin-fixed and paraffin-embedded material.** *Beitr Pathol* 1977, **161**:288-91.
37. Kanazawa H, Ohsawa K, Sasaki Y, Kohsaka S, Imai Y: **Macrophage/microglia-specific protein Iba1 enhances membrane ruffling and Rac activation via phospholipase C-gamma -dependent pathway.** *J Biol Chem* 2002, **277**:20026-32.
38. Babcock AA, Kuziel WA, Rivest S, Owens T: **Chemokine expression by glial cells directs leukocytes to sites of axonal injury in the CNS.** *J Neurosci* 2003, **23**:7922-30.
39. Simard AR, Soulet D, Gowing G, Julien JP, Rivest S: **Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease.** *Neuron* 2006, **49**:489-502.
40. Krum JM, Rosenstein JM: **Transient coexpression of nestin, GFAP, and vascular endothelial growth factor in mature reactive astroglia following neural grafting or brain wounds.** *Exp Neurol* 1999, **160**:348-60.
41. Chaudhry N, de Silva U, Smith GM: **Cell adhesion molecule L1 modulates nerve-growth-factor-induced CGRP-IR fiber sprouting.** *Exp Neurol* 2006, **202**:238-49.
42. Groneberg DA, Niimi A, Dinh QT, Cosio B, Hew M, Fischer A, Chung KF: **Increased expression of transient receptor potential vanilloid-1 in airway nerves of chronic cough.** *Am J Respir Crit Care Med* 2004, **170**:1276-80.
43. Aoki S, Su Q, Li H, Nishikawa K, Ayukawa K, Hara Y, Namikawa K, Kiryu-Seo S, Kiyama H, Wada K: **Identification of an axotomy-induced glycosylated protein, AIGP1, possibly involved in cell death triggered by endoplasmic reticulum-Golgi stress.** *J Neurosci* 2002, **22**:10751-60.
44. Wada R, Tiff CJ, Proia RL: **Microglial activation precedes acute neurodegeneration in Sandhoff disease and is suppressed by bone marrow transplantation.** *Proc Natl Acad Sci USA* 2000, **97**:10954-9.
45. Livak KJ, Schmittgen TD: **Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.** *Methods* 2001, **25**:402-8.
46. Hunter WM, Greenwood FC: **Preparation of iodine-131 labelled human growth hormone of high specific activity.** *Nature* 1962, **194**:495-6.
47. Hock FJ, Wirth K, Albus U, Linz W, Gerhards HJ, Wiemer G, Henke S, Breipohl G, König W, Knolle J: **Hoe 140 a new potent and long acting bradykinin-antagonist: in vitro studies.** *Br J Pharmacol* 1991, **102**:769-73.
48. Nazarali AJ, Gutkind JS, Saavedra JM: **Calibration of 125I-polymer standards with 125I-brain paste standards for use in quantitative receptor autoradiography.** *Neurosci Methods* 1989, **30**:247-53.
49. McCarthy KD, de Vellis J: **Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue.** *J Cell Biol* 1980, **85**:890-902.

50. Noda M, Kariura Y, Amano T, Manago Y, Nishikawa K, Aoki S, Wada K: **Expression and function of bradykinin receptors in microglia.** *Life Sci* 2003, **72**:1573-81.
51. Noda M, Kariura Y, Amano T, Manago Y, Nishikawa K, Aoki S, Wada K: **Kinin receptors in cultured rat microglia.** *Neurochem Int* 2004, **45**:437-42.
52. Hargreaves K, Dubner R, Brown F, Flores C, Joris J: **A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia.** *Pain* 1988, **32**:77-88.
53. Cloutier F, Couture R: **Pharmacological characterization of the cardiovascular responses elicited by kinin B(1) and B(2) receptor agonists in the spinal cord of streptozotocin-diabetic rats.** *Br J Pharmacol* 2000, **130**:375-85.
54. Vianna RM, Ongali B, Regoli D, Calixto JB, Couture R: **Up-regulation of kinin B1 receptor in the lung of streptozotocin-diabetic rat: autoradiographic and functional evidence.** *Br J Pharmacol* 2003, **138**:13-22.
55. Abdouh M, Khanjari A, Abdelazziz N, Ongali B, Couture R, Hassésian HM: **Early upregulation of kinin B1 receptors in retinal microvessels of the streptozotocin-diabetic rat.** *Br J Pharmacol* 2003, **140**:33-40.
56. Campos MM, Ongali B, De Souza Buck H, Schanstra JP, Girolami JP, Chabot JG, Couture R: **Expression and distribution of kinin B1 receptor in the rat brain and alterations induced by diabetes in the model of streptozotocin.** *Synapse* 2005, **57**:29-37.
57. Yerneni KK, Bai W, Khan BV, Medford RM, Natarajan R: **Hyperglycemia-induced activation of nuclear transcription factor kappaB in vascular smooth muscle cells.** *Diabetes* 1999, **48**:855-64.
58. Schanstra JP, Bataillé E, Marin Castaño ME, Barascud Y, Hirtz C, Pesquero JB, Pecher C, Gauthier F, Girolami JP, Bascands JL: **The B1-agonist [des-Arg10]-kallidin activates transcription factor NF-kappaB and induces homologous upregulation of the bradykinin B1-receptor in cultured human lung fibroblasts.** *J Clin Invest* 1998, **101**:2080-91.
59. El Midaoui A, Ongali B, Petcu M, Rodi D, de Champlain J, Neugebauer W, Couture R: **Increases of spinal kinin receptor binding sites in two rat models of insulin resistance.** *Peptides* 2005, **26**:1323-30.
60. Pan ZK, Ye RD, Christiansen SC, Jagels MA, Bokoch GM, Zuraw BL: **Role of the Rho GTPase in bradykinin-stimulated nuclear factor-kappaB activation and IL-1beta gene expression in cultured human epithelial cells.** *J Immunol* 1998, **160**:3038-45.
61. Ifuku M, Färber K, Okuno Y, Yamakawa Y, Miyamoto T, Nolte C, Merrino VF, Kita S, Iwamoto T, Komuro I, Wang B, Cheung G, Ishikawa E, Ooboshi H, Bader M, Wada K, Kettenmann H, Noda M: **Bradykinin-induced microglial migration mediated by B1-bradykinin receptors depends on Ca2+ influx via reverse-mode activity of the Na+/Ca2+ exchanger.** *J Neurosci* 2007, **27**:13065-73.
62. Tsuda M, Ueno H, Kataoka A, Tozaki-Saitoh H, Inoue K: **Activation of dorsal horn microglia contributes to diabetes-induced tactile allodynia via extracellular signal-regulated protein kinase signaling.** *Glia* 2008, **56**:378-86.
63. Hansson E: **Could chronic pain and spread of pain sensation be induced and maintained by glial activation?** *Acta Physiol* 2006, **187**:321-7.
64. Moalem G, Tracey DJ: **Immune and inflammatory mechanisms in neuropathic pain.** *Brain Res Rev* 2006, **51**:240-64.
65. Horowitz SH: **Recent clinical advances in diabetic polyneuropathy.** *Curr Opin Anaesthesiol* 2006, **19**:573-8.
66. Ueda H: **Molecular mechanisms of neuropathic pain-phenotypic switch and initiation mechanisms.** *Pharmacol Ther* 2006, **109**:57-77.
67. Ueda H: **Peripheral mechanisms of neuropathic pain – involvement of lysophosphatidic acid receptor-mediated demyelination.** *Mol Pain* 2008, **4**:11.
68. Lohse MJ, Benovic JL, Codina J, Caron MG, Lefkowitz RJ: **β-arrestin: A protein that regulates β-adrenergic receptor function.** *Science* 1990, **248**:1547-1550.
69. Seachrist JL, Ferguson SS: **Regulation of G protein-coupled receptor endocytosis and trafficking by Rab GTPases.** *Life Sci* 2003, **74**:225-35.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

